GRDN

Guardian Pharmacy Services, Inc. (GRDN) became a public company in 2024. In Q1 2026, the company reported revenue of $336.6 million and diluted EPS of $0.21, updating its full-year 2026 guidance to $1.40 billion to $1.42 billion. The acquisition of Mercury Pharmacy Services in June 2025 expanded Guardian's footprint into the Pacific Northwest. In Q2 2026, reported in August, revenue reached $351.8 million (up 2% year-over-year) and diluted EPS was $0.34, beating estimates, which led to raised full-year 2026 guidance for revenue ($1.43–$1.45 billion) and Adjusted EBITDA ($129–$131 million). Guardian participated in the Jefferies Healthcare Services Investor Conference in August 2026, and acquired Nautilus Pharmacy assets in September 2026. Wall Street analysts have a 'Strong Buy' consensus, with Truist raising its target to $51 from $47 and Oppenheimer lifting its target to $49 from $43 in late 2026. The stock price increased by 34.9% from $30.01 on January 1, 2026, to $40.49 by October 7, 2026, reaching an all-time high of $48.33 in September 2026.